Full article: Comparison of methods for the prediction of human clearance from hepatocyte intrinsic clearance for a set of reference compounds and an external evaluation set
![Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases | Journal of Medicinal Chemistry Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.9b00794/asset/images/medium/jm9b00794_0009.gif)
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases | Journal of Medicinal Chemistry
![Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases | Journal of Medicinal Chemistry Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.9b00794/asset/images/large/jm9b00794_0006.jpeg)
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases | Journal of Medicinal Chemistry
![Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases | Journal of Medicinal Chemistry Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.9b00794/asset/images/medium/jm9b00794_0008.gif)
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases | Journal of Medicinal Chemistry
TECHNISCHE UNIVERSITÄT MÜNCHEN LEHRSTUHL FÜR VERKEHRSTECHNIK UNIV.-PROF. DR.-ING. FRITZ BUSCH Arcisstraße 21, 80333 Münche
![Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases | Journal of Medicinal Chemistry Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.9b00794/asset/images/medium/jm9b00794_0015.gif)